Day 1 - Wednesday, 22 May

 9.00 AMOpening of the workshop 
 9.15 AM

The top 10 important observations of the last year affecting clinical management

Ravindra Gupta, MD, PhD
University College London, United Kingdom

 9.45 AM

Resistance to integrase inhibitors

Anne-Genevieve Marcelin, PharmD, PhD
UPMC, France

 Session 1: The role of the reservoir on clinical decision making
Chair: t.b.c
 10.45 AMBuzon Maria Jose 2019How to measure the reservoir 
María José Buzón, PhD
Vall d'Hebron Research Institute, Spain
 11.15 AM

How does the reservoir influence the clinician's decisions

Carlo Federico Perno, MD, PhD
University of Milan, Italy

 11.45 AMDiscussion 
 1.00 PMLUNCH 
 Session 2: Role of STI management in HIV prevention
Chairs: t.b.c.
 2.00 PMWhitlock, Gary 2019New approaches to STI management
Gary Whitlock, MD
Dean Street Clinic, Chelsea & Westminster Hospital
United Kingdom
 2.20 PMInterplay between PrEP and STI
 2.40 PMCurrent status of PrEP
Will Nutland, DrPH
PrEPster, United Kingdom
 3.00 PMAbstract - driven presentations 
  3.30 PM Panel Discussion 
 Session 3: Clinical management of HIV - related abstracts
Chair: t.b.c.
 4.20 PM Abstract-driven presentations 
 5.20 PMGuided poster tour 1 
 5.20 PMWelcome Reception & Poster Viewing 

Day 2 - Thursday, 23 May

 Session 4: What's in the pipeline? Presentations from scientists from the industry
Chair: t.b.c.
 8.30 AM

Harmony P. Garges, MD,  MPH
Vice President and Head, Global Medical Affairs, ViiV Healthcare, USA

 8.45 AMLuisa Stamm, MD, PhD
Executive Director, HIV and Emerging Viral Infections, Gilead Sciences, USA
  9.00 AMKathleen Squires, MD
Global Director Scientific Affairs-ID/HIV, Merck, USA
  9.15 AMHanneke Schuitemaker,2019Hanneke Schuitemaker, PhD
Vice President, Head Viral Vaccine Discovery and Translational Medicine, Janssen, The Netherlands
  9:30 AM Q&A, discussion 
 10.00 AMGuided poster tour 2 
 10.30 AMCOFFEE BREAK & Poster Viewing 
 12.00 PM LUNCH 
  Session 5: Management of viral Hepatitis I
Chair: t.b.c.
 1.00 PM

Novel compounds for HBV therapy

Pietro Lampertico, MD, PhD
Fondazione Policlinico - University of Milan, Italy

 1.30 PM

Novel markers on HBV / HDV co-infection

Valentina Svicher, PhD
University of Rome Tor Vergata, Italy

 2.00 PMAbstract-driven presentations 
 2.45 PMDiscussion 
 Session 6: Management of viral Hepatitis II
Chair: t.b.c.
 3.30 PM

Clinical relevance of HCV rare subtypes
Slim Fourati, MD, PhD
University of Paris Est, France

 4.00 PMAbstract-driven presentations 
 4.45 PMEnd of Program day 2 

Day 3 - Friday, 24 May

 Session 7: Clinical Management Challenges
Chair: t.b.c.
 8.30 AMReiss, Peter 2019The new patient - with what & when
Peter Reiss, MD, PhD
UMC Amsterdam, The Netherlands
 9.00 AMEugenia, Negredo 2019The aging patient
Eugenia Negredo, PhD
Hospital Universitari Germans Trias i Pujol, Badalona, Spain
  9.30 AM

The pregnant woman - update
Laurent Mandelbrot, MD
Hôpitaux Universitaires Paris Nord, Paris, France

 10.00 AMAbstract - driven presentations 
 10.30 AMCOFFEE BREAK and Guided poster tour 3 
 Session 8: Progress in cure / elimination approaches
Chair: t.b.c.
 11.30 AM

Update on HIV cure research

Linos Vandekerckhove, MD, PhD 
University of Gent, Belgium

 12.00 AM

Hepatitis C elimination research

Angelos Hatzakis, MD, PhD
University of Athens, Greece

 12.30 AM

Perspectives in HBV cure research

Fabien Zoulim, MD
INSERM, France

 13.00 PMDiscussion 
 13.15 PMClosure of the meeting